Q2
Eylea sales jump helps boost Regeneron in Q2 results
August 5, 2016Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results
Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …
Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations
August 2, 2016Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results
Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …
Earnings drop at Sanofi as it looks for a quick Medivation resolution
July 29, 2016Medical Communications, Research and Development 2016, Medivation, Q2, Sanofi, earnings
Sanofi has published its earnings results for Q2, which show a fall in sales and profits as their diabetes division …
Cholesterol drugs drag AstraZeneca’s profits down in latest financial results
July 28, 2016Research and Development, Sales and Marketing 2016, AstraZeneca, Q2, h1, results
AstraZeneca has maintained its financial outlook for 2016, despite its Q2 and H1 results showing sharp falls in core earnings …
Pharma unit helps boost profits at Bayer
July 27, 2016Research and Development, Sales and Marketing Bayer, Q2, results
The pharmaceutical division at Bayer was the driving force, as the company announced a 5.7% increase in second quarter profit …
Gilead lowers full-year guidance as sales and profits down in Q2
July 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing 2016, Gilead, Q2, results
Gilead Sciences has announced its financial results from the second quarter of this year, with sales and profits taking a …
Roche beats forecasts in strong H1 results
July 21, 2016Research and Development, Sales and Marketing 2016, Q2, Roche, h1, results
Roche has published very encouraging full results for the first half of this year, with cancer drug sales helping to …
J&J boosted by pharma revenue in Q2 results
July 20, 2016Research and Development 2016, Johnson and Johnson, Q2, results
Shares at Johnson and Johnson have reached a record high of over $125 after pharma revenues helped to raise full …
Novartis lowers core operating profit outlook in Q2 results
July 19, 2016Manufacturing and Production, Research and Development, Sales and Marketing 2016, Novartis, Q2, results
Novartis has warned that its profits may decline this year as it issued second quarter results, with generic competition for …
Sanofi sees FDA approval for diabetes drug
February 26, 2015Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4
US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …
Pfizer revenue drops, but new cancer drugs shine
July 29, 2014Research and Development, Sales and Marketing Cancer, Inlyta. axitinib, Lipitor, Lyrica, Pfizer, Q2, Sutent, viagra
Pfizer saw a 2% drop in sales for the second quarter but has pointed to the stellar growth of its …
Another major drop in sales for GSK
July 23, 2014Sales and Marketing China, GSK, Q2, Witty, bribery, sales, scandal, sex
GlaxoSmithKline posted a 4% slide in revenue for the second quarter today as its recovery from a slew of patent …
New drugs see J&J sales rise
July 17, 2014Medical Communications, Sales and Marketing J&J, JJ, Q2, hepatitis C, olysio, sovaldi
Johnson & Johnson saw sales rise 9.1% to $19.5 billion year on year on the back of a strong performance …
Merck KGaA declines in Q2
August 7, 2013Sales and Marketing Erbitux, Merck KGaA, Q2, Serono
Sales of cancer drug Erbitux dropped as Merck Serono’s revenues for the second quarter of 2013 dipped year-on-year, the firm …
Seroquel loss hits AstraZeneca
August 2, 2013Sales and Marketing AstraZeneca, Q2, Seroquel, symbicourt
Loss of exclusivity on brands such as the antipsychotic Seroquel IR helped put a $500 million dent in AstraZeneca’s performance …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
